ERBB2 and breast cancer: The phase III DESTINY-Breast04 trial demonstrated that trastuzumab deruxtecan (T-DXd) significantly extended progression-free survival (PFS) by 4.8 months and OS by 6.6 months compared to standard chemotherapy in patients with HER2-low, advanced breast cancer [22].